Literature DB >> 26561042

Mode of delivery and risk of intracranial haemorrhage in newborns with severe haemophilia A: a multicentre study in Gulf region.

H F Nazir1,2, T Al Lawati1, I Beshlawi1, S AlSharidah3, M Elshinawy1,2, F Alkasim4, M F Khanani5, A Tarawa6, T Al Subhi1, A Alrawas1, W Al Riyami1, S Al Kindi1, K Al Saadi7, S Al-Lamki8, Y Wali1,2.   

Abstract

INTRODUCTION: The optimum mode of delivery in a known carrier of a haemophilia A is still an issue of debate. AIM: This study was conducted to report a multicentre experience in Gulf Cooperation Council (GCC) on the incidence of intracranial haemorrhage (ICH) in newborns with severe haemophilia A delivered by different modalities.
METHODS: We have conducted a retrospective/prospective multicentre cohort study including a total of seven hospitals distributed in four GCC countries between 1998 and Jan 2015. A total of 163 patient with severe haemophilia A (factor VIII <1%) were enrolled in this study, age ranged between 2 weeks to 18 years.
RESULTS: Most of the patients were born by spontaneous vaginal delivery (SVD) (131, 80.4%), whereas 26 patients (16%) were born by CS and only six patients were born by instrumental delivery (3.7%), five of them by vacuum and one was delivered using forceps. Five out of 163 patients developed ICH during the first 2 weeks of life (3.1%). Two of them were born by SVD (2/131; 1.5%) and two were born by instrumental delivery (2/6; 33.3%). Only one patient among those who were born by caesarean section developed ICH (1/26; 3.8%). Assisted vaginal delivery was associated with a significant risk of ICH, in comparison to SVD and CS (P = 0.0093).
CONCLUSION: Normal vaginal delivery is still considered a safe journey through the birth canal for haemophilic newborns particularly in this area of the world. Larger prospective studies might be needed to define an evidence-based optimal mode of delivery for the haemophilia carrier expecting an affected child.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Gulf region; haemophilia A; intracranial haemorrhage; mode of delivery

Mesh:

Year:  2015        PMID: 26561042     DOI: 10.1111/hae.12842

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

Review 1.  Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years.

Authors:  Ezio Zanon; Samantha Pasca
Journal:  Blood Transfus       Date:  2018-02-04       Impact factor: 3.443

2.  Regulatory B Cells Are Functionally Impaired in Patients Having Hemophilia A With Inhibitors.

Authors:  Mohamed-Rachid Boulassel; Maryam Al-Ghonimi; Badriya Al-Balushi; Amal Al-Naamani; Zahra Al-Qarni; Yasser Wali; Mohamed Elshinawy; Maryam Al-Shezawi; Hamad Khan; Hanan Nazir; Doaa Khater; Anil Pathare; Salam Al-Kindi
Journal:  Clin Appl Thromb Hemost       Date:  2017-04-10       Impact factor: 2.389

3.  Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy.

Authors:  Scott Dunkley; Julie A Curtin; Anthony J Marren; Robert P Heavener; Simon McRae; Jennifer L Curnow
Journal:  Med J Aust       Date:  2019-03-29       Impact factor: 7.738

4.  Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds.

Authors:  Nadine G Andersson; Elizabeth A Chalmers; Gili Kenet; Rolf Ljung; Anne Mäkipernaa; Hervé Chambost
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

5.  Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian EMO.REC Registry.

Authors:  Ezio Zanon; Samantha Pasca; Francesco Demartis; Annarita Tagliaferri; Cristina Santoro; Isabella Cantori; Angelo Claudio Molinari; Chiara Biasoli; Antonio Coppola; Matteo Luciani; Gianluca Sottilotta; Irene Ricca; Berardino Pollio; Alessandra Borchiellini; Alberto Tosetto; Flora Peyvandi; Anna Chiara Frigo; Paolo Simioni
Journal:  J Clin Med       Date:  2022-04-01       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.